RECOMBINANT PROTEINS AND THEIR THERAPEUTIC USES
A recombinant protein expressing one or more human growth factors, tumor antigens, and/or receptors or epitopes thereof on or within an immunogenic expression creating a recombinant protein in which one or more epitopes are presented on the surface of the sequence in their natural configuration. The growth factor, tumor antigen, and/or receptor, sequence(s) may be expressed within the encoding sequence at appropriate internal positions or at the termini as single expressions or as two or more tandem repeats.
1 .- 33 . (canceled)
34 . A recombinant protein, comprising:
a polypeptide sequence; and
a first sequence expressing at least a portion of a receptor along said polypeptide sequence.
35 . The recombinant protein according to claim 34 , wherein said polypeptide sequence includes an immunogenic polypeptide sequence.
36 . The recombinant protein according to claim 34 , wherein said polypeptide sequence includes a cholera toxin B (CT-B) protein.
37 . The recombinant protein according to claim 34 , wherein said at least said portion of said receptor includes a full length or part thereof of one or more of the following receptors including but not limited to Human Epidermal growth factor Receptor 2 (Her2), Human Epidermal growth factor Receptor 3 (Her3), and other receptors.
38 . The recombinant protein according to claim 37 , wherein said at least said portion of said receptor includes a full length or a portion of two to four different receptors present in said synthetic protein.
39 . The recombinant protein according claim 37 , wherein said at least said portion of said receptor includes a full length or a portion of one or more receptors in said synthetic protein as single epitopes or as two or more tandem repeats.
40 . The recombinant protein according to claim 34 , further comprising a second sequence expressing at least a portion of a growth factor along said polypeptide sequence.
41 . The recombinant protein according to claim 40 , wherein said at least said portion of said growth factor includes a full length or part thereof of one or more of the following growth factors including but not limited to IGF-1, IGF-2, FGF1, FGF2, TGF-α, TGF-β, VEGF-A, VEGF-B, VEGF-C, VEGF, D, PDGF, NGF, EGF, HGF, BMP's, and IL's 1-6.
42 . The recombinant protein according to claim 41 , wherein said at least said portion of said growth factor includes a full length or neutralizing portion of two to four different growth factors present in said synthetic protein.
43 . The recombinant protein according claim 41 , wherein said at least said portion of said growth factor includes a full length or neutralizing portion of one or more growth factors in said synthetic protein as single epitopes or as two or more tandem repeats.
44 . The recombinant protein according claim 41 , wherein said at least said portion of said growth factor or a neutralizing portion thereof is separated from the remaining synthetic protein by a peptide ‘spacer’.
45 . The recombinant protein according claim 44 , wherein said peptide ‘spacer’ comprises in part a growth factor or neutralizing portion thereof.
46 . The recombinant protein according claim 44 , wherein said peptide ‘spacer’ includes one or more T-cell epitopes.
47 . The recombinant protein according to claim 40 , further comprising a third sequence expressing at least a portion of a tumor antigen along said polypeptide sequence.
48 . The recombinant protein according to claim 47 , wherein said tumor antigen is a Prostate Specific Antigen (PSA).
49 . The recombinant protein according to claim 47 , wherein said at least said portion of said tumor antigen includes a full length or part thereof of one or more of the following tumor antigens including but not limited to PSA, and other tumor antigens.
50 . The recombinant protein according to claim 49 , wherein said at least said portion of said tumor antigen includes a full length or a portion of two to four different tumor antigens present in said synthetic protein.
51 . The recombinant protein according claim 49 , wherein said at least said portion of said tumor antigen includes a full length or a portion of one or more tumor antigens in said synthetic protein as single epitopes or as two or more tandem repeats.
52 .- 54 . (canceled)